Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-peptide is a proprietary synthetic peptide developed by Quthero, consisting of the seven-amino acid sequence QHREDGS derived from the fibrinogen-like domain of Angiopoietin-1. It acts as an agonist of the Angiopoietin-1 pathway, specifically targeting the Tie2 receptor to promote cell survival, angiogenesis, and tissue regeneration while reducing inflammation. Quthero is advancing the peptide for multiple regenerative medicine applications, including post-aesthetic procedure skin healing (to reduce redness and swelling), chronic wound regeneration, and cardiovascular indications such as myocardial infarction and peripheral artery disease. The peptide is designed to mimic the regenerative properties of the native Angiopoietin-1 protein in a more stable and deliverable format.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Q-peptide.